ReviewBritish journal of pharmacology2018
Microbial biotransformations in the human distal gut.
Review in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Acute stressor alters inter-species microbial competition for resistant starch-supplemented medium.Gut microbes · 2019Trial
- The faecal bulk heterogeneity: implications for homogenisation and spot-sampling strategies for metabolomic investigations.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Cross-generational mechanisms of maternal gut microbiota in modulating offspring autism spectrum disorder risk: from the gut-brain axis to translational challenges in precision interventions.Frontiers in aging neuroscience · 2025Review
- Views and perspectives on the indoleamines serotonin and melatonin in plants: past, present and future.Plant signaling & behavior · 2024Review
- Approach to the diagnosis and management of dysbiosis.Frontiers in nutrition · 2024Review
- Solid organ transplantation and gut microbiota: a review of the potential immunomodulatory properties of short-chain fatty acids in graft maintenance.Frontiers in cellular and infection microbiology · 2024Review
- Longitudinal gut microbial signals are associated with weight loss: insights from a digital therapeutics program.Frontiers in nutrition · 2024Article
- Fermentation technology as a driver of human brain expansion.Communications biology · 2023Review
- Role of Probiotics and Diet in the Management of Neurological Diseases and Mood States: A Review.Microorganisms · 2022Review
- Is Intestinal Dysbiosis-Associated With Immunosuppressive Therapy a Key Factor in the Pathophysiology of Post-Transplant Diabetes Mellitus?Frontiers in endocrinology · 2022Article
- Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model.BMC pharmacology & toxicology · 2021Article
- Microbial Therapeutics in Neurocognitive and Psychiatric Disorders.Journal of clinical medicine research · 2021Review
- Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease.Journal of clinical and translational hepatology · 2020Review
- Most dominant roles of insect gut bacteria: digestion, detoxification, or essential nutrient provision?Microbiome · 2020Article
- Microbiota-dependent and -independent effects of dietary fibre on human health.British journal of pharmacology · 2020Review
- Article
- Rapid gut microbiome changes in a world-class ultramarathon runner.Physiological reports · 2019Article
- Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis.Movement disorders clinical practice · 2019Review
- Microbial biotransformations in the human distal gut.British journal of pharmacology · 2018Review
- When pharmacology meets the microbiome: new targets for therapeutics?British journal of pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human distal gut is home to a rich and dense microbial community with representatives of all three domains of life which are intricately connected with our physiology and health. The combined genomes of these microbes, collectively called the human microbiome, vastly expand the metabolic capacities of our own genome, allowing us to break down and extract energy from dietary compounds that human enzymes cannot digest. In addition, the variable composition of these communities and their biotransformations might explain inter-individual differences in toxicities, tolerances and efficacies for certain drugs. Recent advances in sequencing technologies and bioinformatics have provided exciting new insights into the genomes of our microbial symbionts, their functional capacities and the interactions between these microbes and their human host. This review summarizes the metabolic conversions of dietary components and pharmaceuticals that take place in the human distal gut, as well as their implications for human health. LINKED ARTICLES: This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.